CyPPAActivator of KCa2.2 and KCa2.3 channels CAS# 73029-73-9 |
2D Structure
- Ascomycin(FK 520)
Catalog No.:BCC1370
CAS No.:104987-12-4
- Dexamethasone acetate
Catalog No.:BCC4775
CAS No.:1177-87-3
- Azathioprine
Catalog No.:BCC4762
CAS No.:446-86-6
- Cyclosporin A
Catalog No.:BCC4773
CAS No.:59865-13-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 73029-73-9 | SDF | Download SDF |
PubChem ID | 909822 | Appearance | Powder |
Formula | C16H23N5 | M.Wt | 285.39 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | >12.85mg/mL in DMSO | ||
Chemical Name | N-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine | ||
SMILES | CC1=CC(=NC(=N1)N2C(=CC(=N2)C)C)NC3CCCCC3 | ||
Standard InChIKey | USEMRPYUFJNFQN-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H23N5/c1-11-10-15(18-14-7-5-4-6-8-14)19-16(17-11)21-13(3)9-12(2)20-21/h9-10,14H,4-8H2,1-3H3,(H,17,18,19) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Activator of small conductance Ca2+-activated K+ channels that displays selectivity for KCa2.2 (SK2) and KCa2.3 (SK3) channels (EC50 values are 5.6 and 14 μM for KCa2.3 and KCa2.2 respectively). Displays no activity at KCa2.1 (SK1) and KCa3.1 (IK) channels. |
CyPPA Dilution Calculator
CyPPA Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.504 mL | 17.5199 mL | 35.0398 mL | 70.0795 mL | 87.5994 mL |
5 mM | 0.7008 mL | 3.504 mL | 7.008 mL | 14.0159 mL | 17.5199 mL |
10 mM | 0.3504 mL | 1.752 mL | 3.504 mL | 7.008 mL | 8.7599 mL |
50 mM | 0.0701 mL | 0.3504 mL | 0.7008 mL | 1.4016 mL | 1.752 mL |
100 mM | 0.035 mL | 0.1752 mL | 0.3504 mL | 0.7008 mL | 0.876 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 15-Isopimarene-8,18-diol
Catalog No.:BCN4287
CAS No.:73002-86-5
- Lidocaine hydrochloride
Catalog No.:BCC9009
CAS No.:73-78-9
- Guanine
Catalog No.:BCN8414
CAS No.:73-40-5
- H-Ile-OH
Catalog No.:BCC2960
CAS No.:73-32-5
- Melatonin
Catalog No.:BCN2196
CAS No.:73-31-4
- Adenine
Catalog No.:BCC4450
CAS No.:73-24-5
- H-Trp-OH
Catalog No.:BCC3111
CAS No.:73-22-3
- Cordycepin
Catalog No.:BCN5389
CAS No.:73-03-0
- L-(-)-threo-3-Hydroxyaspartic acid
Catalog No.:BCC6565
CAS No.:7298-99-9
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
- BMS-707035
Catalog No.:BCC2133
CAS No.:729607-74-3
- XRP44X
Catalog No.:BCC7568
CAS No.:729605-21-4
- Atractylenolide III
Catalog No.:BCN1045
CAS No.:73030-71-4
- Epigomisin O
Catalog No.:BCN2862
CAS No.:73036-31-4
- Atractylenolide I
Catalog No.:BCN1043
CAS No.:73069-13-3
- Atractylenolide II
Catalog No.:BCN1044
CAS No.:73069-14-4
- Praeruptorin A
Catalog No.:BCN4987
CAS No.:73069-25-7
- (+)-Praeruptorin A
Catalog No.:BCN4989
CAS No.:73069-27-9
- Praeruptorin D
Catalog No.:BCN4990
CAS No.:73069-28-0
- Scutebarbatine D
Catalog No.:BCN8536
CAS No.:910099-76-2
- Arecoline
Catalog No.:BCN8537
CAS No.:73069-28-9
- Ferruginine
Catalog No.:BCN1911
CAS No.:73069-63-3
- Fenticonazole nitrate
Catalog No.:BCC8983
CAS No.:73151-29-8
- Effusol
Catalog No.:BCN2928
CAS No.:73166-28-6
CyPPA, a Positive SK3/SK2 Modulator, Reduces Activity of Dopaminergic Neurons, Inhibits Dopamine Release, and Counteracts Hyperdopaminergic Behaviors Induced by Methylphenidate.[Pubmed:22347859]
Front Pharmacol. 2012 Feb 13;3:11.
Dopamine (DA) containing midbrain neurons play critical roles in several psychiatric and neurological diseases, including schizophrenia and attention deficit hyperactivity disorder, and the substantia nigra pars compacta neurons selectively degenerate in Parkinson's disease. Pharmacological modulation of DA receptors and transporters are well established approaches for treatment of DA-related disorders. Direct modulation of the DA system by influencing the discharge pattern of these autonomously firing neurons has yet to be exploited as a potential therapeutic strategy. Small conductance Ca(2+)-activated K(+) channels (SK channels), in particular the SK3 subtype, are important in the physiology of DA neurons, and agents modifying SK channel activity could potentially affect DA signaling and DA-related behaviors. Here we show that cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine (CyPPA), a subtype-selective positive modulator of SK channels (SK3 > SK2 > > > SK1, IK), decreased spontaneous firing rate, increased the duration of the apamin-sensitive afterhyperpolarization, and caused an activity-dependent inhibition of current-evoked action potentials in DA neurons from both mouse and rat midbrain slices. Using an immunocytochemically and pharmacologically validated DA release assay employing cultured DA neurons from rats, we show that CyPPA repressed DA release in a concentration-dependent manner with a maximal effect equal to the D2 receptor agonist quinpirole. In vivo studies revealed that systemic administration of CyPPA attenuated methylphenidate-induced hyperactivity and stereotypic behaviors in mice. Taken together, the data accentuate the important role played by SK3 channels in the physiology of DA neurons, and indicate that their facilitation by CyPPA profoundly influences physiological as well as pharmacologically induced hyperdopaminergic behavior.
CyPPA, a positive modulator of small-conductance Ca(2+)-activated K(+) channels, inhibits phasic uterine contractions and delays preterm birth in mice.[Pubmed:21795518]
Am J Physiol Cell Physiol. 2011 Nov;301(5):C1027-35.
Organized uterine contractions, including those necessary for parturition, are dependent on calcium entry through voltage-gated calcium channels in myometrial smooth muscle cells. Recent evidence suggests that small-conductance Ca(2+)-activated potassium channels (K(Ca)2), specifically isoforms K(Ca)2.2 and 2.3, may control these contractions through negative feedback regulation of Ca(2+) entry. We tested whether selective pharmacologic activation of K(Ca)2.2/2.3 channels might depress uterine contractions, providing a new strategy for preterm labor intervention. Western blot analysis and immunofluorescence microscopy revealed expression of both K(Ca)2.2 and K(Ca)2.3 in the myometrium of nonpregnant (NP) and pregnant (gestation day 10 and 16; D10 and D16, respectively) mice. Spontaneous phasic contractions of isolated NP, D10, and D16 uterine strips were all suppressed by the K(Ca)2.2/2.3-selective activator CyPPA in a concentration-dependent manner. This effect was antagonized by the selective K(Ca)2 inhibitor apamin. Whereas CyPPA sensitivity was reduced in D10 and D16 versus NP strips (pIC(50) 5.33 +/- 0.09, 4.64 +/- 0.03, 4.72 +/- 0.10, respectively), all contractions were abolished between 30 and 60 muM. Blunted contractions were associated with CyPPA depression of spontaneous Ca(2+) events in myometrial smooth muscle bundles. Augmentation of uterine contractions with oxytocin or prostaglandin F(2alpha) did not reduce CyPPA sensitivity or efficacy. Finally, in an RU486-induced preterm labor model, CyPPA significantly delayed time to delivery by 3.4 h and caused a 2.5-fold increase in pup retention. These data indicate that pharmacologic stimulation of myometrial K(Ca)2.2/2.3 channels effectively suppresses Ca(2+)-mediated uterine contractions and delays preterm birth in mice, supporting the potential utility of this approach in tocolytic therapies.
Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels.[Pubmed:17486140]
Br J Pharmacol. 2007 Jul;151(5):655-65.
BACKGROUND AND PURPOSE: Positive modulators of small conductance Ca(2+)-activated K(+) channels (SK1, SK2, and SK3) exert hyperpolarizing effects that influence the activity of excitable and non-excitable cells. The prototype compound 1-EBIO or the more potent compound NS309, do not distinguish between the SK subtypes and they also activate the related intermediate conductance Ca(2+)-activated K(+) channel (IK). This paper demonstrates, for the first time, subtype-selective positive modulation of SK channels. EXPERIMENTAL APPROACH: Using patch clamp and fluorescence techniques we studied the effect of the compound cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine (CyPPA) on recombinant hSK1-3 and hIK channels expressed in HEK293 cells. CyPPA was also tested on SK3 and IK channels endogenously expressed in TE671 and HeLa cells. KEY RESULTS: CyPPA was found to be a positive modulator of hSK3 (EC(50) = 5.6 +/- 1.6 microM, efficacy 90 +/- 1.8 %) and hSK2 (EC(50) = 14 +/- 4 microM, efficacy 71 +/- 1.8 %) when measured in inside-out patch clamp experiments. CyPPA was inactive on both hSK1 and hIK channels. At hSK3 channels, CyPPA induced a concentration-dependent increase in the apparent Ca(2+)-sensitivity of channel activation, changing the EC(50)(Ca(2+)) from 429 nM to 59 nM. CONCLUSIONS AND IMPLICATIONS: As a pharmacological tool, CyPPA may be used in parallel with the IK/SK openers 1-EBIO and NS309 to distinguish SK3/SK2- from SK1/IK-mediated pharmacological responses. This is important for the SK2 and SK1 subtypes, since they have overlapping expression patterns in the neocortical and hippocampal regions, and for SK3 and IK channels, since they co-express in certain peripheral tissues.